Business
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced financing transactions totaling $7.1 million, significantly strengthening the Company's balance sheet and financial position.The transactions include:$1.6 million equity...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced financing transactions totaling $7.1 million, significantly strengthening the Company's balance sheet and financial position.","length":476,"tagName":"p"},{"type":"text","content":"The transactions include:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"$1.6 million equity financing in a non-brokered private placement at $0.15 per unit, with each unit consisting of one common share and one common share purchase warrant exercisable at $0.25 for 36 months, subject to acceleration provisions. This private placement is planned to close on March 6, 2026.","length":301,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"$1.5 million convertible debenture financing from an insider/director, bearing interest at 10% per annum and convertible at $0.15 per share, issued together with 10,000,000 warrants exercisable at $0.25 for 36 months, subject to acceleration provisions. The debenture funds have been advanced and the Company will close this transaction immediately upon TSX acceptance.","length":369,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"$4.0 million equity financing from an insider/director, consisting of 26,666,667 units at $0.15 per unit, each unit including one common share and one common share purchase warrant exercisable at $0.20 for 36 months, subject to acceleration provisions. The close of this transaction is subject to shareholder approval at our Annual General Meeting on April 8, 2026.","length":365,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1035,"olType":false},{"type":"text","content":"Proceeds from the $4.0 million financing will be used to retire the Company's existing $4.0 million secured term loan maturing April 16, 2026, subject to shareholder approval of the equity financing transaction. Including approximately $900,000 raised in a non-brokered private placement in November of 2025, Sernova has raised over $4.0 million in private placement financings over the past ...